-
1
-
-
84861759106
-
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132
-
doi:10.1245/s10434-011-2190-5
-
Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol. 2011. doi:10.1245/s10434-011-2190-5.
-
(2011)
Ann Surg Oncol
-
-
Wang, D.1
Zhang, Q.2
Blanke, C.D.3
Demetri, G.D.4
Heinrich, M.C.5
Watson, J.C.6
-
2
-
-
77951875556
-
NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors
-
Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw. 2010;8(Suppl 2):S1-41.
-
(2010)
J Natl Compr Cancer Netw
, vol.8
, Issue.SUPPL. 2
-
-
Demetri, G.D.1
Von Mehren, M.2
Antonescu, C.R.3
DeMatteo, R.P.4
Ganjoo, K.N.5
Maki, R.G.6
-
3
-
-
77954319411
-
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
ESMO/CONTICANET/EUROBONET Consensus Panel of Experts
-
Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v98-102.
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL. 5
-
-
Casali, P.G.1
Blay, J.Y.2
-
4
-
-
80053465153
-
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)
-
Joensuu H, Eriksson M, Hartmann J, Sundby Hall K, Schútte J, Reichardt A, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol. 2011;15(Suppl, May 20):LBA1.
-
(2011)
J Clin Oncol
, vol.15
, Issue.SUPPL. MAY 20
-
-
Joensuu, H.1
Eriksson, M.2
Hartmann, J.3
Sundby Hall, K.4
Schútte, J.5
Reichardt, A.6
-
5
-
-
62849096370
-
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial
-
Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-104.
-
(2009)
Lancet
, vol.373
, pp. 1097-1104
-
-
Dematteo, R.P.1
Ballman, K.V.2
Antonescu, C.R.3
Maki, R.G.4
Pisters, P.W.5
Demetri, G.D.6
-
6
-
-
78649673624
-
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001
-
Corless CL, Ballman BV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010;28(Suppl, May 20):10006.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. MAY 20
, pp. 10006
-
-
Corless, C.L.1
Ballman, B.V.2
Antonescu, C.3
Blanke, C.D.4
Blackstein, M.E.5
Demetri, G.D.6
-
7
-
-
77949898532
-
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients
-
Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST)
-
Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247-53.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1247-1253
-
-
-
8
-
-
33746401591
-
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
-
DOI 10.1016/j.ejca.2006.01.030, PII S0959804906001754
-
Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093-103. (Pubitemid 44275331)
-
(2006)
European Journal of Cancer
, vol.42
, Issue.8
, pp. 1093-1103
-
-
Debiec-Rychter, M.1
Sciot, R.2
Le, C.A.3
Schlemmer, M.4
Hohenberger, P.5
Van Oosterom, A.T.6
Blay, J.-Y.7
Leyvraz, S.8
Stul, M.9
Casali, P.G.10
Zalcberg, J.11
Verweij, J.12
Van Glabbeke, M.13
Hagemeijer, A.14
Judson, I.15
-
9
-
-
84867300058
-
Frequencies of KIT and PDGFRAmutations in theMolecGIST prospective population-based study differ from those of advanced GISTs
-
doi:10.1007/s12032-011-0074-y
-
Emile JF, Brahimi S,Coindre JM, Bringuier PP,MongesG, Samb P, et al. Frequencies of KIT and PDGFRAmutations in theMolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011. doi:10.1007/s12032-011-0074-y.
-
(2011)
Med Oncol
-
-
Emile, J.F.1
Brahimi, S.2
Coindre, J.M.3
Bringuier, P.P.4
MongesG5
Samb, P.6
-
10
-
-
33750360306
-
Gastrointestinal stromal tumors treated with imatinib: Monitoring response with contrast-enhanced sonography
-
DOI 10.2214/AJR.05.1192
-
Lassau N, Lamuraglia M, Chami L, Leclere J, Bonvalot S, Terrier P, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol. 2006;187:1267-73. (Pubitemid 44630831)
-
(2006)
American Journal of Roentgenology
, vol.187
, Issue.5
, pp. 1267-1273
-
-
Lassau, N.1
Lamuraglia, M.2
Chami, L.3
Leclere, J.4
Bonvalot, S.5
Terrier, P.6
Roche, A.7
Le, C.A.8
-
11
-
-
67349212626
-
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
-
Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;35:739-45.
-
(2009)
Eur J Surg Oncol
, vol.35
, pp. 739-745
-
-
Fiore, M.1
Palassini, E.2
Fumagalli, E.3
Pilotti, S.4
Tamborini, E.5
Stacchiotti, S.6
-
12
-
-
33846635001
-
Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations
-
DOI 10.1245/s10434-006-9228-0
-
Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol. 2007;14:526-32. (Pubitemid 46175297)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.2
, pp. 526-532
-
-
Haller, F.1
Detken, S.2
Schulten, H.-J.3
Happel, N.4
Gunawan, B.5
Kuhlgatz, J.6
Fuzesi, L.7
-
13
-
-
33845619526
-
Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era
-
DOI 10.1245/s10434-006-9047-3
-
Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006;13:1596-603. (Pubitemid 44951467)
-
(2006)
Annals of Surgical Oncology
, vol.13
, Issue.12
, pp. 1596-1603
-
-
Bonvalot, S.1
Eldweny, H.2
Pechoux, C.L.3
Vanel, D.4
Terrier, P.5
Cavalcanti, A.6
Robert, C.7
Lassau, N.8
Cesne, A.L.9
-
14
-
-
33644667084
-
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
-
Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006;93:304-11.
-
(2006)
J Surg Oncol
, vol.93
, pp. 304-311
-
-
Rutkowski, P.1
Nowecki, Z.2
Nyckowski, P.3
Dziewirski, W.4
Grzesiakowska, U.5
Nasierowska-Guttmejer, A.6
-
15
-
-
33744795769
-
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
-
DOI 10.1200/JCO.2005.05.3439
-
Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325-31. (Pubitemid 46630664)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.15
, pp. 2325-2331
-
-
Raut, C.P.1
Posner, M.2
Desai, J.3
Morgan, J.A.4
George, S.5
Zahrieh, D.6
Fletcher, C.D.M.7
Demetri, G.D.8
Bertagnolli, M.M.9
-
16
-
-
34247610583
-
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
-
DOI 10.1097/01.sla.0000236630.93587.59, PII 0000065820070300000003
-
DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245:347-52. (Pubitemid 46673128)
-
(2007)
Annals of Surgery
, vol.245
, Issue.3
, pp. 347-352
-
-
DeMatteo, R.P.1
Maki, R.G.2
Singer, S.3
Gonen, M.4
Brennan, M.F.5
Antonescu, C.R.6
-
17
-
-
34247615184
-
Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST
-
DOI 10.1097/01.sla.0000242710.36384.1b, PII 0000065820070300000002
-
Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245:341-6. (Pubitemid 46673127)
-
(2007)
Annals of Surgery
, vol.245
, Issue.3
, pp. 341-346
-
-
Gronchi, A.1
Fiore, M.2
Miselli, F.3
Lagonigro, M.S.4
Coco, P.5
Messina, A.6
Pilotti, S.7
Casali, P.G.8
-
18
-
-
47149107052
-
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)
-
Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008;98:27-33.
-
(2008)
J Surg Oncol
, vol.98
, pp. 27-33
-
-
Sym, S.J.1
Ryu, M.H.2
Lee, J.L.3
Chang, H.M.4
Kim, T.W.5
Kim, H.C.6
-
19
-
-
77951814300
-
Post-imatinib surgery in advanced/metastatic GIST: Is it worthwhile in all patients?
-
Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2010;21:403-8.
-
(2010)
Ann Oncol
, vol.21
, pp. 403-408
-
-
Mussi, C.1
Ronellenfitsch, U.2
Jakob, J.3
Tamborini, E.4
Reichardt, P.5
Casali, P.G.6
-
20
-
-
77957341199
-
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial
-
Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11:942-9.
-
(2010)
Lancet Oncol
, vol.11
, pp. 942-949
-
-
Le Cesne, A.1
Ray-Coquard, I.2
Bui, B.N.3
Adenis, A.4
Rios, M.5
Bertucci, F.6
|